ACR-2316 — Initial data
2026
Additional ACR-2316 Phase 1/2 clinical data for weekly and bi-weekly dosing regimens and transition into dose expansion in AP3-identified tumor types in 2026Source filing
ACRV biotech catalysts & pipeline
ACRIVON THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
prexasertib (ACR-368) — Interim data
H2 2026
A prespecified simultaneous interim analysis and data update from both all-comer (biopsy-independent) serous EC arms of the ACR-368 Phase 2b study in second half of 2026Source filing
ACR-6840 — IND submission
H1 2027
Submit IND filing to the FDA for ACR-6840, or alternative CDK11 inhibitor candidate, in first half of 2027Source filing
CDK11 inhibitor — IND submission
H1 2027
Submit IND filing to the FDA for CDK11 inhibitor development candidate in first half of 2027Source filing